<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.01">
 <iati-activity default-currency="CAD" hierarchy="1" iati-activities:version="2.01" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-301-2-105168-001</iati-identifier>
  <reporting-org ref="XM-DAC-301-2" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="FR">Innovation pharmaceutique, d&#xE9;livrance de brevets sur des variantes mineures et licences obligatoires</narrative>
   <narrative xml:lang="EN">Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="FR">On constate que de plus en plus de brevets sont d&#xE9;livr&#xE9;s sur des variantes mineures de produits existants, et ce, tant dans les pays industrialis&#xE9;s que dans les pays en d&#xE9;veloppement. Cette tendance a des r&#xE9;percussions particuli&#xE8;res lorsqu&apos;il est question de produits pharmaceutiques. Alors que le nombre de nouvelles entit&#xE9;s chimiques d&#xE9;velopp&#xE9;es a chut&#xE9; consid&#xE9;rablement au cours des dix derni&#xE8;res ann&#xE9;es, le nombre de brevets d&#xE9;livr&#xE9;s pour de simples changements dans la composition chimique ou la formulation de produits pharmaceutiques existants a sans cesse augment&#xE9;. L&apos;utilisation de ces brevets pour emp&#xEA;cher la concurrence de la part de produits g&#xE9;n&#xE9;riques peut freiner l&apos;acc&#xE8;s &#xE0; des m&#xE9;dicaments abordables et constituer un obstacle au droit &#xE0; la sant&#xE9;. La d&#xE9;livrance de brevets sur des variantes mineures de produits pharmaceutiques existants peut notamment obliger les gouvernements &#xE0; recourir &#xE0; des licences obligatoires.

Les pays en d&#xE9;veloppement qui d&#xE9;sirent stimuler l&apos;innovation locale se heurtent donc &#xE0; un dilemme sur le plan des politiques : comment concevoir des politiques en mati&#xE8;re de brevets qui stimulent l&apos;innovation locale tout en assurant un acc&#xE8;s le plus vaste possible aux m&#xE9;dicaments, particuli&#xE8;rement pour les pauvres ? Ce projet permettra de tester l&apos;hypoth&#xE8;se selon laquelle a) en raison des disparit&#xE9;s entre les capacit&#xE9;s d&apos;innovation des industries locales et &#xE9;trang&#xE8;res, les normes peu &#xE9;lev&#xE9;es en mati&#xE8;re de brevetabilit&#xE9; avantageront, au bout du compte, l&apos;industrie &#xE9;trang&#xE8;re; b) l&apos;application d&apos;une norme stricte en mati&#xE8;re d&apos;&#xE9;tape inventive est susceptible d&apos;ouvrir la voie &#xE0; l&apos;innovation et d&apos;am&#xE9;liorer l&apos;&#xE9;tat de sant&#xE9; dans les pays qui obtiennent des brevets. Cette recherche vise &#xE0; d&#xE9;montrer qu&apos;en adoptant des normes de brevetabilit&#xE9; bien d&#xE9;finies, les gouvernements pourraient &#xE9;viter de d&#xE9;penser du capital politique et diplomatique li&#xE9; &#xE0; la d&#xE9;livrance de brevets qui devront &#xEA;tre assujettis &#xE0; une licence obligatoire ou &#xE0; l&apos;utilisation gouvernementale.</narrative>
   <narrative xml:lang="EN">There is growing evidence of a proliferation of patents over minor variants of existing products, both in developed and developing countries. This trend has special implications in the case of pharmaceuticals. While the number of newly-developed chemical entities has dramatically fallen during the last 10 years, the number of patents over simple changes in the chemistry or formulation of existing pharmaceuticals has continuously increased. The use of these patents to exclude generic competition may block access to affordable drugs and constitute an obstacle to the right to health. The granting of patents on minor variants of known pharmaceuticals may, in particular, force governments to resort to granting compulsory licenses.

Developing countries interested in promoting local innovation therefore face a policy dilemma, mainly, how to design patent policies that promote local innovation while ensuring the broadest possible access to medicines, particularly by the poor. The research will test the hypotheses that a) given the asymmetries in innovation capacity between local and foreign industries, low standards of patentability will ultimately benefit the latter and b) the application of a strict inventive step standard is likely to increase room for follow-on innovation and health status in the country of patent grant. The research aims to demonstrate that with the application of well-defined patentability standards, governments could avoid spending political and diplomatic capital associated with compulsory licensing and government use.</narrative>
  </description>
  <participating-org role="1" type="10">
   <narrative xml:lang="FR">Canada. Parlement</narrative>
   <narrative xml:lang="EN">Canada. Parliament</narrative>
  </participating-org>
  <participating-org role="2" type="23">
   <narrative xml:lang="ES">Fundacion Instituto para la Investigacion del Medicamento en los Sistemas de Salud</narrative>
  </participating-org>
  <participating-org role="4" type="23">
   <narrative xml:lang="ES">Fundacion Instituto para la Investigacion del Medicamento en los Sistemas de Salud</narrative>
  </participating-org>
  <participating-org role="3" type="15">
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   <narrative xml:lang="EN">International Development Research Centre</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2009-04-07" type="2"></activity-date>
  <activity-date iso-date="2011-04-07" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
   </organisation>
   <telephone>(+1) 613-236-6163</telephone>
   <email>info@idrc.ca</email>
   <website>http://www.idrc.ca</website>
   <mailing-address>
    <narrative xml:lang="FR">CP 8500, Ottawa ON Canada, K1G 3H9</narrative>
    <narrative xml:lang="EN">PO Box 8500, Ottawa ON Canada, K1G 3H9</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="3"></activity-scope>
  <recipient-country code="IN" percentage="20"></recipient-country>
  <recipient-country code="ZA" percentage="20"></recipient-country>
  <recipient-region code="X3" percentage="60" vocabulary="1"></recipient-region>
  <sector code="00001" percentage="100" vocabulary="99">
   <narrative xml:lang="FR">Autre</narrative>
   <narrative xml:lang="EN">Other</narrative>
  </sector>
  <sector code="32168" percentage="100" vocabulary="1"></sector>
  <policy-marker code="1" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="3" significance="2" vocabulary="1"></policy-marker>
  <policy-marker code="4" significance="2" vocabulary="1"></policy-marker>
  <policy-marker code="5" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1"></policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2010-05-31"></transaction-date>
   <value currency="CAD" value-date="2010-05-31">93000</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="ES">Fundacion Instituto para la Investigacion del Medicamento en los Sistemas de Salud</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2010-06-30"></transaction-date>
   <value currency="CAD" value-date="2010-06-30">-8000</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="ES">Fundacion Instituto para la Investigacion del Medicamento en los Sistemas de Salud</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2010-09-30"></transaction-date>
   <value currency="CAD" value-date="2010-09-30">84286</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="ES">Fundacion Instituto para la Investigacion del Medicamento en los Sistemas de Salud</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2011-07-31"></transaction-date>
   <value currency="CAD" value-date="2011-07-31">39653</value>
   <provider-org>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="ES">Fundacion Instituto para la Investigacion del Medicamento en los Sistemas de Salud</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <conditions attached="1">
   <condition type="2">
    <narrative xml:lang="EN">Grant is conditional on completion of specified terms of reference, receipt of specified deliverables</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de respecter le mandat &#xE9;tabli et de livrer les r&#xE9;sultats attendus</narrative>
   </condition>
   <condition type="3">
    <narrative xml:lang="EN">Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de p&#xE9;riodiquement pr&#xE9;senter une justification d&#xE9;taill&#xE9;e de l&apos;utilisation des fonds vers&#xE9;s par le CRDI ainsi qu&apos;une estimation budg&#xE9;taire de la p&#xE9;riode de rapport suivante</narrative>
   </condition>
  </conditions>
 </iati-activity>
</iati-activities>
